Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) is projected to announce its Q4 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $105.30 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, May 6th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $104.85 million for the quarter, compared to analysts’ expectations of $111.90 million. Accuray had a negative net margin of 10.76% and a negative return on equity of 79.43%.

Accuray Trading Down 3.6%

ARAY stock traded down $0.01 during midday trading on Wednesday, hitting $0.30. The stock had a trading volume of 64,693 shares, compared to its average volume of 2,161,221. The company’s 50-day moving average price is $0.30 and its 200 day moving average price is $0.43. The company has a debt-to-equity ratio of 3.21, a current ratio of 1.42 and a quick ratio of 0.66. The firm has a market cap of $35.69 million, a PE ratio of -0.81 and a beta of 1.39. Accuray has a 12-month low of $0.22 and a 12-month high of $2.10.

Institutional Trading of Accuray

Several institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in Accuray in the third quarter valued at $35,000. Tower Research Capital LLC TRC increased its stake in Accuray by 604.2% during the second quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 30,182 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Accuray by 32.4% during the third quarter. BNP Paribas Financial Markets now owns 39,369 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 9,633 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Accuray in the 3rd quarter worth about $73,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Accuray in the 4th quarter worth about $41,000. 64.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ARAY. Jefferies Financial Group cut Accuray from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Weiss Ratings upgraded Accuray from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Finally, BTIG Research reiterated a “neutral” rating on shares of Accuray in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Accuray currently has an average rating of “Reduce” and a consensus price target of $2.00.

Accuray Company Profile

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.